Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home News room Press releases
Press Releases

2010


25/08/2010
ABLYNX ANNOUNCES HALF YEAR RESULTS FOR 2010
NL

19/08/2010
ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2010 WITH WEBCAST
NL

27/07/2010
ABLYNX ANNOUNCES CHANGE IN MANAGEMENT
NL

23/07/2010
ABLYNX ANNOUNCES WARRANT EXERCISE
NL

12/07/2010
NOVARTIS OBTAINS LICENSES TO DEVELOP AND COMMERCIALISE TWO NOVEL NANOBODIES®
NL

05/07/2010
ABLYNX SECURES €1.5 MILLION IN GRANTS
NL

28/06/2010
ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR THE SECOND YEAR IN A ROW
NL

22/06/2010
ABLYNX EXPANDS INTO NEW R&D FACILITIES
NL

15/06/2010
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 5th ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE
NL

02/06/2010
ABLYNX AND REMYND SETTLE DISPUTE AMICABLY
NL

24/05/2010
NANOBODY® LEAD CANDIDATE SELECTED BY BOEHRINGER INGELHEIM FOR DEVELOPMENT IN ALZHEIMER'S DISEASE
NL

20/05/2010
ABLYNX ANNOUNCES A THIRD EXTENSION OF ITS ANTI-TNF-ALPHA NANOBODY COLLABORATION WITH PFIZER
NL

19/05/2010
ABLYNX PROVIDES A BUSINESS UPDATE FOR THE FIRST QUARTER 2010
NL

30/04/2010
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
NL

23/04/2010
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
NL

13/04/2010
SPO OVER-ALLOTMENT OPTION PARTIALLY EXERCISED
NL

26/03/2010
ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERY
NL

25/03/2010
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
NL

18/03/2010
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
NL

15/03/2010
ABLYNX SUCCESSFULLY RAISES €50 MILLION WITH SECONDARY PUBLIC OFFERING - FINAL PRICE: €7.5 PER SHARE
NL

08/03/2010
ABLYNX INTENDS TO RAISE UP TO €57.5 MILLION WITH SECONDARY PUBLIC OFFERING - PRICE RANGE: €7.20 - €7.75 PER SHARE
NL

25/02/2010
ABLYNX PLANS A SECONDARY PUBLIC OFFERING ON EURONEXT BRUSSELS
NL

25/02/2010
ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
NL

22/02/2010
ABLYNX RESPONDS TO PRESS REPORTS
NL

22/02/2010
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST
NL

19/02/2010
ABLYNX RECEIVES €1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061
NL

11/02/2010
ABLYNX WINS PATENT OPPOSITION CASE AGAINST DOMANTIS (GSK)
NL

11/02/2010
ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE
NL

22/01/2010
ABLYNX ANNOUNCES WARRANT EXERCISE
NL

11/01/2010
ABLYNX SUCCESSFULLY GENERATES NANOBODIES® AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME
NL

06/01/2010
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 28TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
NL








































 

Press releases

  • 2010

News archive

Email alerts

If you would like to receive updates on the company news, please
click here